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Myeloid-derived suppressor cells (MDSCs) dampen the immune response thorough inhibition of T cell activa-
tion and proliferation and often are expanded in pathological conditions. Here, we studied the fate of MDSCs 
in cancer. Unexpectedly, MDSCs had lower viability and a shorter half-life in tumor-bearing mice compared 
with neutrophils and monocytes. The reduction of MDSC viability was due to increased apoptosis, which was 
mediated by increased expression of TNF-related apoptosis–induced ligand receptors (TRAIL-Rs) in these 
cells. Targeting TRAIL-Rs in naive mice did not affect myeloid cell populations, but it dramatically reduced the 
presence of MDSCs and improved immune responses in tumor-bearing mice. Treatment of myeloid cells with 
proinflammatory cytokines did not affect TRAIL-R expression; however, induction of ER stress in myeloid 
cells recapitulated changes in TRAIL-R expression observed in tumor-bearing hosts. The ER stress response 
was detected in MDSCs isolated from cancer patients and tumor-bearing mice, but not in control neutrophils 
or monocytes, and blockade of ER stress abrogated tumor-associated changes in TRAIL-Rs. Together, these 
data indicate that MDSC pathophysiology is linked to ER stress, which shortens the lifespan of these cells in 
the periphery and promotes expansion in BM. Furthermore, TRAIL-Rs can be considered as potential targets 
for selectively inhibiting MDSCs.
Introduction
Myeloid-derived suppressor cells (MDSCs) are widely considered 
as an important factor regulating immune responses to different 
pathologic conditions. Accumulation of these cells is a common 
occurrence in cancer and many other pathologic conditions (1). 
MDSCs constitute a heterogeneous group of cells consisting pri-
marily of immature myeloid cells with morphological and pheno-
typic characteristics similar to those of monocytes and polymor-
phonuclear neutrophils (PMNs) (referred to herein as M-MDSCs 
and PMN-MDSCs, respectively) (1–3). MDSCs have a distinct gene 
expression profile and a number of biochemical and functional 
differences from normal monocytes and PMNs (4, 5). Expansion 
of MDSCs in cancer is controlled by several growth factors and 
cytokines, with GM-CSF being the most prominent (6, 7). However, 
the fate of MDSCs in tumor-bearing (TB) hosts remains poorly 
understood. The fact that MDSCs accumulate in large numbers 
could suggest that these cells have mechanisms protecting them 
from apoptosis. Indeed, studies have demonstrated several mech-
anisms that could promote MDSC survival. These mechanisms 
include TNFR2 signaling, which supports MDSC survival through 
upregulation of cellular FLICE-inhibitory protein (c-FLIP) and inhi-
bition of caspase-8 activity (8), signaling mediated via IL-4α receptor 
(9), and decreased cell surface expression of FAS receptor, leading to 
diminished expression of IRF8 and BAX as well as increased levels 
of BCL-XL (10). MDSCs induced in highly inflammatory settings 
had increased resistance to FAS-mediated apoptosis (11). On the 
other hand, Sinha et al. demonstrated the possibility of CTLs kill-
ing MDSCs via FAS-FASL–mediated apoptosis (12). Nonetheless, 
unbiased analysis of the fate of MDSCs in cancer has been lacking. 
The initial goal of this study was to investigate the kinetics of MDSC 
homeostasis in different organs in vivo. To our surprise, our data 
revealed that MDSCs had much shorter lifespan than their coun-
terpart PMNs and monocytes in tumor-free mice. Further investi-
gation demonstrated that this effect was mediated by changes in 
the expression of TNF-related apoptosis–induced ligand receptors 
(TRAIL-Rs) caused by ER stress response in these cells.
Results
MDSC survival in TB mice. To monitor MDSC homeostasis, we 
administered BrdU to EL4 TB mice for 8 days in drinking water 
(pulse phase), followed by its withdrawal for 4 days (chase phase). 
PMNs and PMN-MDSCs (in naive and TB mice, respectively) were 
defined as CD11b+Ly6G+Ly6Clo, and monocytes and M-MDSCs 
as CD11b+Ly6G–Ly6Chi (Supplemental Figure 1A; supplemen-
tal material available online with this article; doi:10.1172/
JCI74056DS1). TB mice had a dramatic increase of MDSCs in 
spleens and peripheral blood (PB), where PMN-MDSCs repre-
sented more than 90% of all MDSCs (2, 13). M-MDSCs incorpo-
rated BrdU significantly faster than monocytes (Figure 1A). PMN-
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MDSCs had the same rate of BrdU uptake as PMNs (Figure 1B). 
In contrast to M-MDSCs, PMN-MDSCs do not proliferate 
(13), which explains the different kinetics of BrdU accumula-
tion observed between M-MDSCs and PMN-MDSCs (Figure 1, 
A and B). During the chase phase, we observed significantly accel-
erated loss of BrdU positivity by PMN-MDSCs compared with 
PMNs (Figure 1C). These differences were not due to different 
kinetics of replacement of labeled cells, since during the pulse 
phase, PMNs and PMN-MDSCs had similar rates of BrdU incor-
poration. Therefore, PMN-MDSCs either migrated to different 
organs or died faster than PMNs. To test these possibilities, we 
isolated the total population of Gr1+CD11b+ MDSCs from BM of 
EL4 TB mice and immature myeloid cells (IMCs), with the same 
phenotype and purity, from naive mice as a control (Supplemen-
tal Figure 1B). MDSCs and IMCs were separately labeled with 
2 fluorescent cell trackers (CMFDA and DDAO, mixed at a 1:1 
ratio), and then injected i.v. into EL4 TB mice. At 6 hours after 
transfer, the MDSC/IMC ratio in spleens and tumors in the recip-
ients remained the same (1:1; Figure 1D). However, when cells 
were evaluated 20 hours after transfer, the presence of MDSCs in 
spleen, tumor, and lung was lower than that of IMCs (Figure 1, 
E and F). The same results were obtained when the 2 cell trackers 
were switched between the cells (data not shown), which indicates 
that the observed differences were not the artifact of the cell label-
ing. The total number of cells evaluated in each organ was rela-
tively small. However, the large differences in MDSC/IMC ratios 
between different tissues suggests that blood contamination was 
not directly responsible for those changes.
Next, we studied the proliferation and survival of these cells in 
vitro. In these experiments, in addition to the total population of 
BM-derived MDSCs, we also used spleen PMN-MDSCs and PMNs 
(Supplemental Figure 1C). Since the numbers of M-MDSCs and 
monocytes in spleen are low, these cells were not used in these 
experiments. The recovery of BM MDSCs and spleen PMN-MDSCs 
after overnight culture (without cytokines) was significantly lower 
than IMCs and PMNs from naive mice (Figure 1G). No differences 
Figure 1
MDSCs have shorter survival than their naive counterparts. (A–C) BrdU pulse-chase analysis of MDSC turnover (n = 3 mice per time point). 
(A and B) BrdU+ cells in PB monocytes and M-MDSCs (A) and in PB PMNs and PMN-MDSCs (B) during pulse. (C) BrdU+ cells in PMNs and 
PMN-MDSCs in blood and spleen during chase. (D–F) MDSC/IMC ratio in different organs 6 (D) or 20 (E and F) hours after i.v. injection of 
MDSC/IMC mix (1:1 ratio) into TB recipients. (D and E) 1 representative experiment. Cell count and percentages of boxed regions are indi-
cated. (F) Combined results; each symbol represents 1 mouse (n = 4). (G) Recovery of myeloid cells isolated from BM or spleen of control or 
EL4 TB mice, after 20 hours of culture in complete media without cytokines (n = 3). 2 × 105 purified cells were plated at the beginning of culture. 
(H) Naive and EL4 TB mice were injected i.p. with 12% casein 20 and 4 hours prior to harvesting of peritoneal fluid. Ly6G+ cells were purified 
using magnetic beads and cultured overnight in complete media without cytokines. Shown is the proportion of surviving cells (relative to input) 
in 3 samples per group. (I) Purified IMCs and MDSCs were labeled with 2 different cell trackers (1:1 CMFDA/DDAO). Labeled cells were cul-
tured alone in medium or mixed at a 1:5 ratio with freshly isolated splenocytes or with tumor, lung, or liver cells, then cultured overnight in com-
plete media. The MDSC/IMC ratio was then calculated (n = 3). P values are compared with medium alone. *P < 0.05; **P < 0.01; ***P < 0.001.
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in the low levels of proliferation were observed between MDSCs 
and IMCs (data not shown). To ascertain that the observed differ-
ences did not simply reflect the activated state of PMN-MDSCs, 
myeloid cells were mobilized to peritoneum of naive or EL4 TB 
mice with repeated i.p. injections of casein. The survival of Ly6G+ 
cells isolated from the peritoneal cavity of TB mice and cultured 
overnight was significantly lower than that of cells isolated from 
naive mice (Figure 1H), which indicates that the observed differ-
ences in MDSC and IMC survival were not caused by differences 
in the activation state of the cells.
To assess the effect of the tissue microenvironment on cell sur-
vival, BM MDSCs and IMCs were mixed with cells obtained from 
different organs of TB mice and cultured overnight, and total cell 
number and MDSC/IMC ratio were evaluated. The low level of 
MDSC survival was not improved by the presence of splenocytes. 
It was increased in the presence of tumor and lung cells, but still 
remained lower than IMCs. Only liver provided equal protection 
for MDSCs and IMCs (Figure 1I). Thus, these data indicated that 
in many tissues, MDSCs exhibit worse survival than IMCs.
PMN-MDSCs rapidly undergo apoptosis mediated by DR5. Caspase-3 
and annexin V staining revealed that BM MDSCs and spleen 
PMN-MDSCs had significantly higher levels of apoptosis than BM 
IMCs and spleen PMNs, respectively (Figure 2, A and B). Increased 
apoptosis was not associated with changes in BCL-2, BCL-XL, or 
cleaved caspase-9, but with an increased amount of cleaved cas-
pase-8 (Figure 2C). Inhibition of caspase-8 with the specific inhibi-
tor Z-IETD-FMK (14) substantially reduced apoptosis of MDSCs 
(Figure 2D), which suggests that this process was mediated by cas-
pase-8 and most likely involved the extrinsic death receptor path-
way (15). To evaluate whether MDSCs are more prone to apoptosis 
Figure 2
MDSCs undergo rapid apoptosis mediated by upregulation of DR5 expression. (A and B) Apoptosis was analyzed based on percentages 
of cleaved caspase-3+ cells after 3 hours in culture (A) and of annexin V+ cells after 6 hours (B). Results represent the average of 4 different 
experiments. (C) Amount of BCL-2, BCL-XL, cleaved caspase-8, cleaved caspase-9, and cleaved caspase-3 was determined after a 3-hour 
culture of cells by Western blot. 3 experiments were performed with the same results. (D) Cells were cultured in the presence of the caspase-8 
inhibitor Z-IETD-FMK (100 μM) or DMSO (control), and the percentage of apoptotic cells (cleaved caspase-3+) was determined after 3 hours. 
Representative results of 3 different experiments are shown. (E) Receptor expression in BM IMCs or MDSCs, determined using quantitative 
RT-PCR. Results represent the average of 3 different samples. (F and G) DR5 expression on the surface of PMN-MDSCs (F) or M-MDSCs 
(G) in spleens of different TB mice or from control PMNs (F) or monocytes (G) isolated from corresponding C57BL/6 or Balb/c mice (3–5 differ-
ent samples). (H) DR5 expression on the surface of PMN-MDSCs and M-MDSCs from spleen (solid line) or tumor site (dotted line) from EL4 
TB mice. Gray filled histogram, isotype control. Results are representative of 4 different experiments. *P < 0.05.
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in vivo than their control counterparts, we used TUNEL staining 
in frozen spleen sections from EL4 TB and control mice. Very few 
Gr1+ cells in control spleens were TUNEL+, whereas the proportion 
of apoptotic cells among Gr1+ cells in TB mice was 5 times higher 
(Supplemental Figure 2).
To elucidate the mechanism of MDSC apoptosis, we analyzed 
the expression of known death receptors. No differences between 
MDSCs and IMCs were found in the expression of Tnfr1, Rank, 
or Fas, nor in the amount of FAS protein on the surface of the 
cells (Figure 2E and Supplemental Figure 3A). In contrast, expres-
sion of Trailr2 (also known as Tnfrsf10b and Dr5) was dramatically 
higher in MDSCs than in IMCs (Figure 2E). TNF-related apop-
tosis–induced ligand receptors (TRAIL-Rs) are members of the 
TNF receptor superfamily and consist of 2 death receptors, DR4 
(also known as TRAIL-R1 and CD261; absent in mice) and DR5 
(also known as TRAIL-R2 and CD262), 2 decoy receptors, DCR1 
(also known as CD263) and DCR2 (also known as CD264), and 
1 soluble receptor, osteoprotegerin (OPG) (16, 17). Spleen PMN-
MDSCs from mice bearing different transplantable tumors and 
spontaneous model of pancreatic carcinoma (KPC) had a sig-
nificantly higher level of surface DR5 than corresponding PMNs 
from naive mice (Figure 2F). Similar results were obtained with 
M-MDSCs and monocytes (Figure 2G).
MDSCs present in tumor tissues of EL4 TB mice had substan-
tially higher DR5 expression than MDSCs in spleens of the same 
mice (Figure 2H). Upregulation of DR5 was also observed in 
MDSCs obtained from the livers and lungs of TB mice (Supple-
mental Figure 3B). No differences in the amount of decoy TRAIL-
Rs were found between MDSCs and IMCs (Supplemental Figure 3, 
C and D). We tested the possible effect of PMN activation on DR5 
expression in casein-mobilized PMNs and PMN-MDSCs. PMN-
MDSCs in peritoneal fluid of casein-treated TB mice had signifi-
cantly higher DR5 expression than did PMNs in naive mice ana-
lyzed under the same conditions (Supplemental Figure 3E).
Targeting of MDSCs using DR5. To determine whether TRAIL-Rs 
play a role in MDSC survival, we inhibited TRAIL signaling with 
OPG, a soluble decoy receptor for RANKL and TRAIL (18). Over-
night culture of cells in the presence of OPG improved MDSC 
survival in a dose-dependent manner, but did not affect IMC 
survival (Figure 3A). To study the implication of TRAIL signal-
ing on MDSC survival, we used myeloid cells from Dr5 KO mice 
(19, 20). Lack of DR5 did not affect differentiation of myeloid cells 
in vitro (data not shown). Reconstitution of the myeloid compart-
ment remained unchanged between recipients reconstituted with 
BM from WT and Dr5 KO mice after lethal irradiation (data not 
shown). In mice reconstituted with Dr5 KO BM cells, EL4 tumors 
grew slightly faster than in mice reconstituted with WT BM cells 
(P > 0.1). However, lack of DR5 resulted in a significant increase in 
the proportion of MDSCs in TB mouse spleen (P < 0.05), but not 
liver (Figure 3B). Dr5 KO MDSCs had significantly lower apoptosis 
Figure 3
TRAIL-R is a potential target for MDSC removal. (A) IMCs and MDSCs (2 × 105 plated) were cultured in complete media overnight in the 
presence of different concentrations of recombinant OPG. Results represent the average number of cells recovered at the end of culture 
(n = 3). (B and C) Congenic CD45.1+ WT mice were lethally irradiated and reconstituted with WT or Dr5 KO BM cells. (B) 3 weeks after tumor 
inoculation, mice were sacrificed, and the presence of CD11b+Gr1+ MDSCs in spleen and liver was analyzed. (C) MDSCs were isolated from 
spleens and cultured in complete media. After 3 hours, the percentage of cleaved caspase-3+ cells was assessed by flow cytometry (results 
are representative of 5 experiments). (D) Number of cells recovered after overnight culture of 2 × 105 MDSCs (results of 5 different samples). 
(E and F) Naive CD45.1+ mice were lethally irradiated and reconstituted with a 1:1 mix of BM cells from CD45.2+ Dr5 KO and CD45.1+ WT 
mice (106 cells). 5 weeks after reconstitution, mice were inoculated s.c. with EL4 cells, and spleens were collected 3 weeks later. The percent-
age of WT (CD45.1+) and Dr5 KO (CD45.2+) cells was analyzed in spleens among different cell populations. (E) Typical example of results. 
(F) Cumulative results of 3 experiments. *P < 0.05; **P < 0.01.
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after a 3-hour culture and significantly higher survival after over-
night incubation than WT MDSCs (Figure 3, C and D), indicative 
of an important role of DR5 in MDSC survival. To verify these 
observations, we performed experiments using mixed BM chime-
ra. Naive CD45.1+ mice were lethally irradiated and reconstituted 
with a 1:1 mix of BM cells from CD45.2+ Dr5 KO and CD45.1+ WT 
mice. Mice were inoculated with EL4 cells at 5 weeks after reconsti-
tution, then analyzed 3 weeks later. CD45.1+ WT cells were preva-
lent in the total population of donor’s cells in spleens (CD45.1+ 
WT, 60%–70%; CD45.2+ Dr5 KO, 30%–40%). However, when the 
population of MDSCs and their subsets were evaluated, Dr5 KO 
cells represented the vast majority of the cells (>70%; Figure 3, 
E and F). These results strongly suggested that Dr5 KO MDSCs 
had a survival advantage over WT MDSCs.
Figure 4
DR5 targeting results in selective MDSC elimination. (A and B) Splenic PMNs and PMN-MDSCs were cultured overnight in complete media 
supplemented with 10 ng/ml GM-CSF, in a plate coated with MD5-1 mAb or control IgG (10 μg/ml). After 20 hours, percentages of annexin V+ cells 
(A) and survival (B) were determined. Results are representative of 3 different experiments. (C) Total MDSCs, PMN-MDSCs, and M-MDSCs in 
EL4 TB spleens, measured by flow cytometry. Treatment with control IgG and MD5-1 mAb (100 μg) was initiated on day 17 after tumor inoculation, 
when tumor diameter reached 1.5 cm, and repeated on days 20 and 23; mice were sacrificed on day 24. (n = 4). (D) EG7 TB mice were treated 
with MD5-1 mAb (100 μg) and/or anti-CD8 mAb (200 μg) or left untreated, and tumor growth was determined (n = 4 per group). (E) On day 28 after 
tumor inoculation, mice were sacrificed; splenic T cells were enriched and stimulated in the presence of control DCs, loaded with OVA or irrelevant 
protein. IFN-γ secretion was assessed by Elispot after 48 hours of restimulation (n = 3). (F) Naive (freshly isolated) or activated (3 days culture 
with 100 ng/ml SIINFEKL) OT-I splenocytes were stimulated with control or specific peptide (100 ng/ml SIINFEKL) in the presence of control IgG 
or MD5-1 mAb (10 μg/ml). IFN-γ secretion was assessed by Elispot after 48 hours of restimulation (n = 3). (G) EL4 TB mice were treated with 
anti-CTLA4 and/or anti–MD5-1 mAb (100 μg each) or left untreated, and tumor growth was determined (n = 4 per group). *P < 0.05; **P < 0.01.
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Our data suggested that high DR5 expression might be a unique 
characteristic of MDSCs. Thus, we tested the possibility of selective 
targeting MDSCs using an agonistic DR5 antibody, MD5-1 mAb. 
Myeloid cells were cultured in the presence of GM-CSF to sup-
port their survival. Treatment with MD5-1 mAb caused apoptosis 
of PMN-MDSCs, but not PMNs, which resulted in a significant 
decrease in PMN-MDSC survival (P < 0.05), but not PMN survival, 
after a 20-hour culture (Figure 4, A and B).
To test the effect of MD5-1 mAb in vivo, we used EL4 cells and 
their OVA-expressing derivate (EG7 cells, which are resistant to 
MD5-1 mAb) in contrast to 4T1 mammary carcinoma, an exam-
ple of DR5-sensitive tumor (Supplemental Figure 4). In mice 
bearing large EL4 tumors (1.5 cm in diameter), treatment with 
3 injections of MD5-1 mAb strongly decreased the accumulation 
of both MDSC subsets (Figure 4C). The effect of MD5-1 mAb was 
quite specific for MDSCs, since the presence of other populations 
of myeloid cells (DCs and macrophages) was not changed, and 
the proportion of T and B cells was increased (likely due to the 
effect of MDSC depletion) (Supplemental Figure 5). Treatment 
with MD5-1 mAb alone was able to significantly delay tumor 
progression in mice bearing immunogenic EG7 tumor (P < 0.05; 
Figure 4D). The antitumor effect was mediated by CD8+ T cells, 
since it was abrogated by the administration of CD8 antibody 
(Figure 4D), and MD5-1 mAb treatment resulted in a substantial 
increase in the number of OVA-specific CD8+ T cells (∼10-fold; 
Figure 4E). Since activated T cells express DR5 (21, 22), we tested 
Figure 5
Short life-span of MDSCs contributes to their expansion. (A–F) Naive mice received 1 injection of 250 μg anti-Gr1 mAb to deplete PMNs from 
the periphery, then examined 2 (A–C) and 4 (D–F) days after treatment. (A and D) Gr1 depletion was assessed in blood and spleen; typical 
results are shown. (B, C, E, and F) Mice were then injected with BrdU i.p. and sacrificed 4 hours later. (B and E) BM IMCs, assessed by flow 
cytometry (n = 3). (C and F) BrdU incorporation in BM IMCs (CD11b+Ly6C+ cells gated), assessed by flow cytometry. Shown are 1 representa-
tive sample (left) and cumulative results (right; n = 3). (G) 3 weeks after EL4 inoculation, TB WT or Dr5 KO mice were injected i.p. with BrdU 
for 4 hours, and spleen MDSCs were analyzed for BrdU incorporation (percent BrdU+ cells). Shown are 1 representative sample (left) and 
cumulative results (right; n = 3). (H) Mice were injected i.p. with 250 μg Gr1 or control IgG mAb. The absolute number of monocytes and PMNs 
was determined in spleens 9 days after injection (n = 3). *P < 0.05; **P < 0.01.
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the possibility that triggering of the receptor could result in acti-
vation of T cells. No direct effect of MD5-1 mAb on the response 
of transgenic OT-1 T cells was observed (Figure 4F).
CTLA4 antibody has been used to enhance the generation of 
tumor-reactive CD8+ T cells (23). By itself, this antibody had no sig-
nificant effect on the growth of established poorly immunogenic 
EL4 tumor (Figure 4G). However, the combination of CTLA4 and 
MD5-1 antibodies resulted in a remarkable retardation of tumor 
growth (P < 0.01; Figure 4G). These results indicate that elimina-
tion of MDSCs via targeting of DR5 in combination with CTLA4 
blockade results in a potent antitumor effect.
Short lifespan of MDSCs can contribute to their expansion and accumu-
lation. Since it is known that lymphodepletion can induce homeo-
static proliferation of lymphocytes (24), we hypothesized that the 
reduced survival of MDSCs in the periphery could contribute 
to increased production of these cells in the BM. To model this 
situation in tumor-free mice, we used Gr1-specific mAb, which 
effectively depleted Gr1+ PMNs and monocytes in PB and spleens 
48 hours after its administration, but had little effect on the cells 
in BM (Figure 5, A and B). At that time, BM IMCs from Gr1 mAb–
treated mice had higher proliferation than cells from untreated 
control mice (Figure 5C). 2 days later, PMNs and monocytes 
remained depleted in the periphery, but IMCs significantly accu-
mulated in BM (Figure 5, D and E). The proliferation of BM IMCs 
remained significantly increased in mice depleted of Gr1+ cells 
in the periphery (Figure 5F). Dr5 KO MDSCs, which had longer 
Figure 6
ER stress response drives TRAIL-R upregulation in MDSCs. (A and B) Hematopoietic progenitor cells were cultured for 5 days in the pres-
ence of 20 ng/ml GM-CSF. (A) DR5 expression on the surface of PMNs stimulated for 24 hours in the presence of IL-1β, TNF-α, IL-6, IFN-γ, or 
tunicamycin (TUN) or left unstimulated (NS). Results of 3 experiments are shown. (B) DR5 expression on the surface of PMNs and monocytes 
stimulated with tunicamycin (dotted line) or left unstimulated (solid line) for 24 hours. Gray filled histogram, isotype control. Shown is 1 repre-
sentative experiment of 4. (C and D) Purified PMNs from BM were treated overnight with thapsigargin (THG) or left untreated. DR5 expression 
(C) and cell viability (D) were assessed by flow cytometry (n = 3). (E and F) Electron microscopy analysis of cell morphology. PMNs and PMN-
MDSCs (E) and monocytes and M-MDSCs (F) were isolated from spleen of control and EL4 TB mice. Shown are representative microphoto-
graphs (arrows denote ER dilation) and the proportion of cells with each ER dilation score (see Methods). Scale bars: 1 μm. (G) Chop, Xbp1, 
Atf4, and Bip expression in splenic PMNs and PMN-MDSCs, determined using quantitative RT-PCR. Results are from 3 different samples. 
(H and I) Spliced XBP1 and CHOP in PMNs and PMN-MDSCs from EL4 TB mice (H) or KPC TB mice (spleen cells only; I), determined by 
Western blot. Results are representative of 4 different samples. *P < 0.05; **P < 0.01.
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lifespan than WT MDSCs, also had significantly lower prolifera-
tion than WT MDSCs (Figure 5G). We then sought to determine 
whether myeloid cell accumulation would be observed in spleen 
when the effect of antibody in periphery had stopped. 9 days after 
treatment with Gr1 mAb, mice had splenomegaly and more than 
doubled total splenocyte numbers compared with control IgG–
treated controls (Supplemental Figure 6, A and B). The propor-
tion and absolute number of both monocytes and PMNs were 
significantly higher in spleen of Gr1 mAb–treated mice than in 
control spleens (Supplemental Figure 5H and Supplemental Fig-
ure 6C). Together, these data suggest that the shortened lifespan 
of MDSCs in the periphery can stimulate the proliferation of their 
precursors in BM, supporting their expansion in TB hosts.
Mechanism of the regulation of DR5 expression in MDSCs. DR5 expres-
sion in tumor cells can be induced by NF-κB, which is regulated 
by proinflammatory cytokines (25). We asked whether increased 
DR5 expression in MDSCs could be mediated by various proin-
flammatory cytokines present in tumor milieu. Treatment of BM 
IMCs from naive mice with IL-1β, IL-6, TNF-α, or IFN-γ in the 
absence or presence of tumor explant supernatants (TES) failed 
Figure 7
Human MDSC survival and TRAIL-R expression. (A) Human PMN-MDSCs and PMNs were isolated from blood of NSCLC patients and cultured 
overnight in complete media. The percentage of cells was determined by flow cytometry at the beginning and end of culture, and the total num-
ber of surviving PMN-MDSCs and PMNs was calculated (n = 3). (B and C) Human PMN-MDSCs and PMNs were cultured in complete media 
supplemented with 10 ng/ml GM-CSF, in the presence of agonistic anti-DR5 mAb (200 ng/ml) (B) or recombinant TRAIL (100 ng/ml) (C), and the 
percentage of surviving cells was determined (n = 3). (D) DR4, DR5, DCR1, and DCR2 expression on the surface of PMN-MDSCs and PMNs 
from the blood of healthy donors (HD) or NSCLC patients. (E) DCR1 and DCR2 expression in PMNs (solid line) and PMN-MDSCs (dotted line). 
Gray filled histogram, isotype control. Results show a typical example of 6 different patient samples. (F) DR5, DCR1, and DCR2 expression on 
the surface of blood or tumor PMN-MDSCs from 5 HNC patients and PMNs from healthy donors. *P < 0.05; **P < 0.01.
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to upregulate DR5 expression (Figure 6A and data not shown). 
We confirmed that, at selected concentrations, those cytokines 
activated their respective signaling pathways: NF-κB, STAT1, and 
STAT3 (Supplemental Figure 7). DR5 expression in tumor cells 
can also be induced by ER stress via spliced XBP1, a major media-
tor of the IRE1 pathway, and C/EBP homologous protein (CHOP), 
a downstream molecule of the PERK pathway (24, 26–29). The ER 
stress inducer tunicamycin caused significantly increased DR5 
expression in BM PMNs and monocytes (Figure 6, A and B). We 
confirmed these results by treating BM PMNs with thapsigargin, 
another ER stress inducer (Figure 6C). Upregulation of DR5 was 
associated with significantly decreased PMN survival (Figure 6D). 
Thapsigargin did not affect the expression of decoy TRAIL-Rs 
(Supplemental Figure 8A). Consistent with lack of the effect on 
DR5 expression, TES alone did not induce the ER stress response 
in murine PMNs (Supplemental Figure 8B).
To evaluate the possible biological significance of these find-
ings, we examined whether signs of ER stress could be found in 
MDSCs directly isolated from TB mice. One of the hallmarks of 
ER stress is enlargement of the ER (30). Using electron micros-
copy, we observed an increased percentage of cells with dilated 
ER in spleen PMN-MDSCs compared with PMNs from EL4 TB 
mice (Figure 6E). Similar results were observed in M-MDSCs 
compared with monocytes (Figure 6F). Expression of several ER 
stress response pathway markers — Chop, Xbp1, Bip, and Atf4 — 
was significantly upregulated in PMN-MDSCs compared with 
PMNs (Figure 6G). The amounts of these proteins in spleen 
PMN-MDSCs from EL4 TB mice and from mice with sponta-
neous pancreatic cancer were higher than in PMNs from naive 
or WT mice (Figure 6, H and I). We also tested the possible 
effect of PMN activation on the ER stress response in casein-
mobilized PMNs and PMN-MDSCs. PMN-MDSCs in peritoneal 
fluid of casein-treated TB mice had substantially higher spliced 
XBP1 and CHOP expression than did PMNs analyzed under the 
same conditions in naive mice (Supplemental Figure 8C). Thus, 
MDSCs exhibited clear signs of the ER stress response.
Human MDSCs are sensitive to TRAIL-induced cell death. To assess 
the survival of MDSCs in cancer patients, we isolated the popu-
lation of CD11b+CD33+CD14–CD15+ PMN-MDSCs from the 
mononuclear fraction of PB of patients with non–small cell lung 
cancer (NSCLC) (Supplemental Figure 9). These cells represent 
the most abundant group of MDSCs in patients with many types 
of cancer (31, 32). PMNs, with the same phenotype, were puri-
fied from PB of the same patients and from healthy donors using 
the standard neutrophil isolation protocol (33). PMNs survived 
20 hours in culture without cytokines significantly better than 
did PMN-MDSCs (P < 0.01; Figure 7A). Targeting TRAIL-Rs with 
either human DR5 agonistic antibody or recombinant TRAIL did 
not affect PMN survival, but significantly reduced PMN-MDSC 
survival (Figure 7, B and C).
We then analyzed TRAIL-R expression and found that, in contrast 
to mice, PMNs and PMN-MDSCs did not differ in the expression 
of surface DR4 or DR5 (Figure 7D). However, PMN-MDSCs from 
NSCLC patients had markedly lower expression of decoy recep-
Figure 8
ER stress response modulates TRAIL-R expression in human MDSCs. (A) Amounts of spliced XBP1 and CHOP in PMNs and PMN-MDSCs 
purified from healthy donor or NSCLC patient blood, determined by Western blot. Results are representative of 5 different samples. (B) Human 
PMNs from healthy donors were cultured in complete media supplemented with 10 ng/ml GM-CSF for 24 hours in the presence of 1 μM 
thapsigargin. DCR1 and DCR2 expression was assessed by flow cytometry. Shown are representative flow histograms and percentage of MFI 
decrease (n = 3). (C and D) Healthy donor PMNs were cultured with GM-CSF for 48 hours in the presence of 20% TCM (PCI30 cells). (C) Chop, 
Xbp1, Atf4, and Bip expression, determined by quantitative RT-PCR. Results represent the average of 4 different samples (D) PMNs were 
preincubated with 500 μg/ml TUDCA (Calbiochem) for 3 hours prior to the addition of TCM. After culture, cells were harvested, and DCR1 and 
DCR2 expression was analyzed. Data are mean ± SD of 4 different samples. *P < 0.05.
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from healthy donors with thapsigargin and observed decreased 
DCR1 and DCR2 expression, but no change in DR5 (Figure 8B 
and data not shown). A 48-hour incubation of PMNs from healthy 
donors with head and neck tumor cell (PCI30) conditioned 
medium (TCM) in the presence of GM-CSF induced marked 
upregulation of the ER stress response in these cells and caused sig-
nificant downregulation of DCR1 and DCR2 (Figure 8, C and D). 
To test the possibility that the effect of TCM on TRAIL-R decoy 
expression was caused by ER stress, we used the well-known ER 
stress inhibitor TUDCA (tauroursodeoxycholic acid, sodium salt; 
ref. 34). TUDCA completely abrogated TCM-inducible downregu-
lation of DCR1 and DCR2 in PMNs (Figure 8D).
ER stress inducers upregulated DR5 expression in human 
tumor cells (Figure 9A). We asked why this effect was not observed 
in human PMNs. Deacetylation of the DR5 promoter could regu-
late the expression of the receptor. We treated mouse PMNs (in 
tors DCR1 and DCR2 (Figure 7, D and E). To verify and extend 
these findings, we evaluated samples from patients with head and 
neck cancer (HNC). TRAIL-R expression on MDSCs from PB and 
tumors was compared in the same patients. Although no differ-
ence in DR5 expression was seen, DCR1 expression was significant-
ly lower in PB PMN-MDSCs than PB PMNs from healthy donors 
(Figure 7F). PMN-MDSCs from tumor site had markedly lower 
DCR1 expression than PB PMN-MDSCs in the same patients, and 
a similar trend was seen for DCR2 expression (Figure 7F).
ER stress response is activated in human MDSCs and modulates decoy 
TRAIL-Rs. Next, we tested whether ER stress response was activated 
in human MDSCs. PMN-MDSCs from NSCLC patients exhibited 
strong upregulation of spliced XBP1 and CHOP protein expres-
sion compared with PMNs from the same patients or from healthy 
donors (Figure 8A). To test the possibility that the ER stress 
response could directly affect DCR expression, we treated PMNs 
Figure 9
Mechanism of different regulation of DR5 in human and mouse PMNs. (A) SK-MEL melanoma tumor cells and MDA231 breast cancer cells 
were treated overnight with thapsigargin (dotted line) or left untreated (solid line), and DR5 expression was assessed by flow cytometry. Gray 
filled histogram, isotype control. Typical result is shown. (B) Mouse PMNs were purified from BM of naive mice and cultured for 24 hours in 
the presence of thapsigargin in combination with VPA. DR5 expression was assessed by flow cytometry (n = 3). (C) Effect of VPA and THG 
combination on DR5 expression in PMNs. DR5 expression was assessed by flow cytometry. Gray filled histogram, isotype control; black solid 
line, untreated; gray solid line, VPA alone; dotted line, VPA plus THG. Shown is 1 representative staining of 3 different experiments. (D) ChIP 
of DR5 promoter with acetylated histone H3 or acetylated histone H4 antibodies in healthy donor PMNs and the SK-MEL melanoma cell line 
cultured overnight with or without VPA. Results are expressed as DNA enrichment normalized to corresponding input value. (E) Potential 
role of ER stress and TRAIL-Rs in the fate of MDSCs.
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IMCs with the same phenotype from control mice. In this situa-
tion, evaluation of apoptosis in remaining cells likely would lead 
to skewed results. In their study, Sinha et al. did not address the 
spontaneous apoptosis or survival of MDSCs; they demonstrated 
that MDSCs are sensitive to FAS/FASL-induced apoptosis (12), 
which does not contradict our results.
We found that shorter survival of MDSCs was caused by cas-
pase-8–dependent apoptosis via upregulation of DR5. Agonistic 
DR5 antibodies and recombinant TRAIL have been previously 
used to target tumor cells in several clinical trials with modest 
results (9, 16, 17), partially attributed to the variability of TRAIL-
R expression in tumor cells. Myeloid cells, although expressing 
TRAIL, have low TRAIL-R expression and thus are resistant to kill-
ing by recombinant TRAIL (40). Our data indicated that targeting 
DR5 in mice did not affect PMNs and IMCs, but effectively elimi-
nated MDSCs. This resulted in significant antitumor effects in 
immunogenic tumors and markedly promoted antitumor effects 
of immune therapy using CTLA4 blockade in weakly immuno-
geneic tumors. In previous studies, treatment of mice bearing 
DR5-expressing tumors with agonistic MD5-1 mAb resulted in 
antitumor effects (41, 42). These effects were associated with the 
generation of antitumor immune responses, but whether it was 
the result of a direct antitumor effect of the antibody or was medi-
ated via other mechanisms remained unclear. Our data demon-
strated that targeting DR5 improved antitumor responses in mice 
bearing TRAIL-insensitive tumors and that these responses were 
mediated by CD8+ T cells. Thus, it is likely that the elimination of 
MDSCs by anti-DR5 antibody treatment facilitated the expansion 
and function of antitumor CD8+ T cells.
In cancer patients, PMN-MDSCs also had lower survival than 
PMNs, and agonistic DR5 antibody as well as recombinant TRAIL 
killed these cells in vitro while not affecting PMNs. However, the 
mechanism of this effect was somewhat different. PMN-MDSCs 
had the same DR5 expression as did PMNs, but substantially 
lower DCR1 and DCR2 expression. The role of decoy receptors in 
TRAIL-mediated signaling is poorly understood. However, DCR2 
may provide antiapoptotic signals neutralizing TRAIL-R signal-
ing, whereas DCR1 inhibits TRAIL-induced apoptosis by com-
peting for TRAIL binding (43, 44). This may explain why human 
PMN-MDSCs, in contrast to PMNs, were sensitive to TRAIL.
What could cause the changes in TRAIL-Rs in MDSCs? In 
recent years, it has become apparent that MDSC accumulation 
requires 2 sets of signals: one induces emergency myelopoi-
esis and affects myeloid cell differentiation, the other activates 
MDSCs. The first group of signals is mediated primarily by 
growth factors such as GM-CSF and G-CSF, and the second by 
proinflammatory cytokines (IL-1β, IL-6, IFN-γ, and IL-4) (1, 6, 7). 
Coincidently, NF-κB triggered by many proinflammatory factors 
regulates TRAIL-R expression (45). To our surprise, neither TCM 
nor a number of cytokines known to be present in the tumor 
milieu were able to upregulate DR5 in mouse IMCs to mimic the 
effect observed in mouse MDSCs.
Since the ER stress response was previously implicated in the 
regulation of TRAIL-Rs (46), we tested its possible role in DR5 
expression in myeloid cells. The ER stress response pathway is a 
complex network responsible for maintaining ER homeostasis 
and is initiated by 3 protein sensors, PERK, IRE1 and ATF6, each 
of which activates a branch of the ER stress response (47). It has 
been implicated in cell differentiation, glucose metabolism, and 
TLR signaling (30). CHOP is usually considered the main media-
which ER stress inducers were able to upregulate DR5 expres-
sion) with the pan-HDAC inhibitor valproic acid (VPA), alone 
or in combination with thapsigargin. In these experiments, VPA 
did not modulate the effect of thapsigargin on DR5 (Figure 9B). 
However, in human PMNs, treatment with VPA restored the 
ability of thapsigargin to induce DR5 expression (Figure 9C). To 
verify the DR5 promoter acetylation in human PMNs, we per-
formed a ChIP assay. Treatment of tumor cells (as a control) with 
VPA did not affect the already high level of acetylated histone 
in the DR5 promoter. In contrast, VPA dramatically increased 
its level in PMNs (Figure 9D). These results indicate that DR5 
promoter silencing by HDACs in human PMNs may prevent the 
upregulation of DR5 expression.
Discussion
Here, we present evidence that accumulation of MDSCs in TB 
mice and in cancer patients is not associated with increased sur-
vival of these cells. On the contrary, MDSCs had substantially 
shorter lifespan than PMNs and monocytes. This was evident in 
spleen, lung, and tumor tissues. In contrast, survival of MDSCs 
in liver was indistinguishable from that of IMCs, and DR5 defi-
ciency did not affect MDSC accumulation in the liver. These 
data are consistent with several observations demonstrating 
that the liver is a site of large MDSC accumulation in TB mice 
and chronic infections (35, 36). Spleen is one of the major sites 
of MDSC expansion in TB mice. Our results indicative of a hos-
tile spleen environment for MDSCs are surprising. However, 
the fact that spleen is a major source of extramedullar myelo-
poiesis in TB mice and the data on high monocyte turnover in 
spleens (37, 38) may suggest that MDSCs rapidly leave spleen 
and are being replaced with newly produced cells. Short sur-
vival of MDSCs in TB mice can stimulate proliferation of their 
precursors and further trigger their expansion (Figure 9E). We 
modeled this situation in tumor-free mice by using Gr1 mAb 
in vivo, which depletes Gr1+ PMNs and monocytes in spleen 
and PB, but not in BM (39). Depletion of the Gr1+ cells in the 
periphery resulted in a significant increase in Gr1+ IMC prolif-
eration and subsequent accumulation of these cells in BM, and 
spleen later on. This mechanism could promote expansion of 
MDSCs. Our hypothesis was further supported by experiments 
demonstrating that Dr5 KO MDSCs had substantially better 
survival than WT MDSCs, which was associated with signifi-
cantly decreased proliferation of MDSCs.
The data on poor MDSC survival were counterintuitive in light 
of our findings regarding MDSC accumulation and were different 
from previous reports showing decreased apoptosis in MDSCs 
(10, 12). The main difference of our study was that we traced the 
fate of MDSCs in vivo using BrdU labeling and adoptive transfer 
and assessed apoptosis of MDSCs without isolation of cells in 
spleen sections. Isolation of cells from spleens involving red cell 
lyses, use of magnetic beads, or sorting usually results in loss of 
some MDSCs. If these cells were in advanced stages of apoptosis, 
this would likely result in enrichment for cells with less apoptosis 
at the time of evaluation. In our study, when cells were cultured 
in vitro for as little as 3 hours, apoptosis in MDSCs became much 
more prominent than in cells with the same phenotype isolated 
from healthy mice. Hu and colleagues measured apoptosis of 
MDSCs after 24 hours culture and showed that it was slightly 
lower that in control cells (10). However, usually less than 20% 
of MDSCs survived 24 hours of culture, in contrast to 40% of 
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Balb/c mice. This number of cells established a s.c. tumor 1–1.5 cm in 
diameter within 2–3 weeks of injection. EL4 and EG7 thymomas, LLC lung 
carcinoma, CT26 colon carcinoma, and 4T1 mammary carcinoma were 
obtained from ATCC. Tumor cells were cultured in DMEM (BioSource 
International) supplemented with 10% FBS, 5 mM glutamine, and 1% anti-
biotics (Invitrogen). KPC mice were described previously (52).
Mice were treated with 200 μg anti-CD8 mAb (clone 53-6.72; BioXCell), 
100 μg anti-CTLA4 mAb (clone 9D9; BioXCell), 250 μg anti-Gr1 mAb 
(clone RB6-8C5; BioXCell), or 100 μg anti-DR5 mAb (clone MD5-1).
Cell isolation and culture. Single-cell suspensions were prepared from 
spleens and BM, red blood cells were removed using ammonium chlo-
ride lysis buffer, and Gr1+ or Ly6G+ cells were isolated subsequently using 
magnetic beads isolation using biotinylated Gr1 antibody (eBiosciences) 
or Ly6G antibody (Miltenyi). Cells were purified using streptavidin beads 
and MACS column according to the manufacturer’s recommendation 
(Miltenyi). Human PMN-MDSCs were isolated on gradient (33), followed 
by labeling with CD15-PE mAb (BD Biosciences), and then separated using 
anti-PE beads and MACS column (Miltenyi). Tissues were first digested 
with collagenase D (Sigma), and then red blood cells were lysed. Cells were 
then culture in RPMI (Biosource International) supplemented with 10% 
FBS, 5 mM glutamine, 25 mM HEPES, 50 μM β-mercaptoethanol, and 1% 
antibiotics (Invitrogen). In some experiments, recombinant GM-CSF was 
added to the culture media at a concentration of 10 ng/ml (Invitrogen). To 
assess TRAIL-mediated killing, mouse cells were cultured in plates pre-coat-
ed with Protein A (Pierce) followed by coating with 10 μg/ml MD5-1 mAb. 
Human cells were cultured in the presence of either 200 ng/ml anti-human 
DR5 agonistic mAb (R&D) or 100 ng/ml recombinant TRAIL (R&D). To 
inhibit TRAIL signaling, mouse cells were cultured in the presence of 
recombinant murine OPG (R&D) at different concentrations.
Flow cytometry. mAbs specific for the mouse cell surface markers CD11b, 
CD11c, Gr1, Ly6G, and Ly6C and for the human cell surface markers 
CD11b, CD14, CD15, and CD33 were purchased from BD Biosciences. 
DR5-specific mAb was purchased from eBiosciences; DCR1- and DCR2-
specific antibodies were purchased from R&D Systems. Cleaved caspase-3 
intracellular staining was performed using BD Cytofix/Cytoperm kit 
and staining with antibody specific for cleaved caspase-3 according to 
the manufacturer’s recommendation (BD Biosciences). Annexin V stain-
ing was performed in annexin V buffer (BD Biosciences) according to the 
manufacturer’s recommendations. BrdU labeling in vivo was performed by 
injection of BrdU i.p. 4 hours prior to cell harvest, and BrdU staining was 
performed using a BrdU Flow kit (BD Biosciences) according to the manu-
facturer’s recommendations. Flow cytometry data were acquired using a 
BD LSR II flow cytometer and analyzed using FlowJo software (Tree Star).
Western blotting. Cells were lysed in RIPA buffer (Sigma-Aldrich) in the pres-
ence of protease inhibitor cocktail (Sigma-Aldrich). Whole-cell lysates were 
subjected to 10%–12% SDS-PAGE and transferred to PVDF membranes. 
Membranes were probed with appropriate primary antibodies overnight at 
4°C: antibodies against BCL-2, BCL-XL, CHOP (human), cleaved caspase-3, 
cleaved caspase-8, and cleaved caspase-9 were from Cell Signaling Technol-
ogy Inc.; antibodies against CHOP (mouse) and spliced XBP1 were from 
Santa Cruz Biotechnology Inc.; antibodies against DCR1 and DCR2 were 
from Abcam. Membranes were washed and incubated 2 hours at room tem-
perature with secondary antibody conjugated with horseradish peroxidase 
(Santa Cruz Biotechnology Inc.). Results were visualized by chemilumines-
cence detection using a commercial kit (Pierce). To confirm equal loading, 
membranes were stripped and reprobed with antibody against β-actin (Santa 
Cruz Biotechnology Inc.) or GAPDH (Cell Signaling Technology Inc.).
Quantitative RT-PCR. RNA was extracted with total RNA extraction kit 
(Omega Bio-tek). cDNA was synthesized (cDNA reverse transcriptase 
kit; Applied Biosystems), and PCR was performed in duplicate for each 
tor of ER stress response–induced apoptosis (26) and is a known 
transcription factor able to directly regulate DR5 expression 
(10, 27). Our experiments demonstrated that treatment of mouse 
IMCs and PMNs with the ER stress inducers tunicamycin and 
thapsigargin resulted in upregulation of DR5, recapitulating the 
effects observed in MDSCs. Treatment of human PMNs with ER 
stress inducers did not affect DR5, but markedly downregulated 
DCR1 and DCR2, similar to the changes observed in MDSCs 
from cancer patients. These data are consistent with a previous 
report showing that thapsigargin could decrease TRAIL decoy 
receptor expression in giant cell tumor of bone (48). Human 
TCM, in contrast to mouse TES, induced the ER stress response 
in PMNs. Inhibition of ER stress by TUDCA abrogated TCM-
inducible downregulation of TRAIL decoy receptors on human 
PMNs. The mechanism by which ER stress can downregulate 
TRAIL decoy receptors remains to be elucidated. Our present 
data demonstrated that MDSCs in TB mice and cancer patients 
exhibit markedly higher levels of ER stress response than their 
tumor-free mouse and healthy donor counterparts. Several fac-
tors could induce ER stress in MDSCs. MDSCs are known to 
have high level of ROS, one of the major inducers of the ER stress 
response (49). Lipids represent another potent ER stress inducer 
(50), and lipid accumulation was shown to be associated with 
DCs (51) and other myeloid cells (data not shown). The tumor 
microenvironment may provide an additional source of ER stress 
inducers associated with low pH, adenosine release, and hypoxia. 
Stronger changes in TRAIL-R expression observed in human 
and mouse MDSCs from tumor sites compared with MDSCs 
from PB and spleen may support this conclusion. Whether ER 
stress directly contributes to the suppressive activity of MDSCs 
remains to be elucidated.
In conclusion, our results suggest a direct role of the ER stress 
response in the fate of MDSCs in TB hosts and implicate TRAIL-
Rs in this process (Figure 9E). Changed expression of TRAIL-R 
patterns (agonist or decoy) can distinguish MDSCs from normal 
PMNs and monocytes. Targeting TRAIL-Rs can result in rapid 
and marked selective depletion of these cells in cancer patients 
and possibly in other pathologic conditions. This approach can 
be explored in efforts to enhance the antitumor effect of various 
immunotherapeutic agents.
Methods
Human samples. Samples were collected from patients at H. Lee Moffitt 
Cancer Center and Helen F. Graham Cancer Center. PB was collected from 
11 subjects with previously untreated stage II–IV NSCLC at H. Lee Moffitt 
Cancer Center and 6 patients with NSCLC at Helen F. Graham Cancer 
Center. In addition, PB and tumor tissues were collected from 5 patients 
with stage III HNC at H. Lee Moffitt Cancer Center. PB from 8 healthy 
donors was used as control.
All cell samples were analyzed within 3 hours of collection. PMN-MDSCs 
were evaluated in mononuclear fraction of PB after ficoll density gradient. 
Neutrophils were evaluated from the cell fraction remaining after removal 
of mononuclear cells. Cells were resuspended in PBS and loaded on a step 
density gradient (Percoll 63% on top of Percoll 72%) to separate PMNs in a 
monolayer between the 2 Percoll phases.
Mice and tumor model. C57BL/6 and Balb/c female mice (6–8 weeks old) 
were obtained from NCI. Mice were kept in pathogen-free conditions. For 
experiments with DR5-deficient mice, lethally irradiated congenic CD45.1+ 
mice (NCI) were reconstituted with BM cells from Dr5 KO mice (19). To 
establish tumors, 5 × 105 tumor cells were injected s.c. into C57BL/6 or 
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in up to one-third of the cytoplasm area; 2, cells containing dilated ER seg-
ments in over one-third and up to two-thirds of the cytoplasm area; 3, cells 
containing dilated ER segments in over two-thirds of the cytoplasm area.
ELISPOT. The number of IFN-γ–producing T cells in response to cog-
nate antigen was assessed in an ELISPOT assay (53). Each well contained 
105 cells. The number of spots was determined in triplicate using an auto-
mated ELISPOT counter (Cellular Technology).
Statistics. Unless otherwise indicated, data are presented as mean ± SEM. 
Statistical analysis was performed using 2-tailed Student’s t test and 
GraphPad Prism 5 software (GraphPad Software Inc.). Tumor measure-
ments were analyzed using 2-way ANOVA and 2-tailed t test. A P value less 
than 0.05 was considered significant.
Study approval. Human studies were approved by the Institutional 
Review Boards of the University of South Florida, the Christiana Care 
Health System at the Helen F. Graham Cancer Center, and The Wistar 
Institute. All patients signed approved consent forms. Animal studies 
were approved by The Wistar Institute and the University of South Florida 
Animal Care and Use Committees.
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sample. To detect expression of cytokines and β-actin, PCR was per-
formed with 12.5 μl SYBR Master Mixture (Applied Biosystems) and 
the following primers: Dr5, 5′-TGCGTTGCTGCTTGCTGTGCT-3′ and 
5′-GGTCCTCTTGATGGGCTCTCCTCC-3′; Dcr1, 5′-GGTTCCTCTTGCT-
GCTGCTGCTGA-3′ and 5′-TCCGGTCACTGGTGGCAGAACAG-3′; Dcr2, 
5′-GGAAATGGTGGCCGACTGCTCAG-3′ and 5′-GGTACATGGGCG-
GCACGATTCTG-3′; Fas, 5′-TCCTGCAGGAGGATGAAACAAGCC-3′ and 
5′-GCTGGCAGCATTGATGGTGAGGT-3′; Tnfr1, 5′-GGCCACCTGGTC-
CGATCATCTTAC-3′ and 5′-TGGATGTATCCCCATCAGCAGAGC-3′; 
Rank, 5′-ACTGAGGAGACCACCCAAGGAGGC-3′ and 5′-ACCAGCA-
CAACGGTCCCCTGAG-3′; Atf4, 5′-ATGGCCGGCTATGGATGAT-3′ 
and 5′-CGAAGTCAAACTCTTTCAGATCCATT-3′; Bip, 5′-CATGGTTCT-
CACTAAAATGAAAGG-3′ and 5′-GCTGGTACAGTAACAACT-3′; Chop, 
5′-CTGCCTTTCACCTTGGAGAC-3′ and 5′-CGTTTCCTGGGGATGAGA-
TA-3′; Xbp1, 5′-AAGAACACGCTTGGGAATGG-3′ and 5′-ACTCCCCTTG-
GCCTCCAC-3′; Actb, 5′-ACCGCTCGTTGCCAATAGTGATGA-3′ and 
5′-TGAGAGGGAAATCGTGCGTGACAT-3′. Expressions of the different 
genes were normalized to Actb. Relative expression was calculated using 
the 2–ΔΔCt method.
ChIP assay .  ChIP was performed using the Acetyl-histone 
Immunoprecipitation Assay kit (Millipore) as previously described (13). 
The DNA was amplified by quantitative PCR using primers specific for 
the DR5 promoter sequence (5′-AGGTTAGTTCCGGTCCCTTC-3′ and 
5′-CAACTGCAAATTCCACCACA-3′).
Electron microscopy. More than 2 × 105 cells were fixed in 3% glutaralde-
hyde in 0.1M sodium phosphate buffer (pH 7.4) and embedded as a pellet 
in low gelling temperature agarose (Sigma-Aldrich). Cells were postfixed 
in 1% osmium tetroxide in 0.1% sodium phosphate buffer (pH 7.4) and 
stained in 2% uranyl acetate. The cells were washed with distilled water 
and dehydrated using an acetone gradient. They were gradually embed-
ded in the araldite resin and cured for 18 hours at 65°C. The ultrathin 
sections (100 nm thick) were collected on 200 mesh copper grids, stained 
with Reynold’s lead citrate, and carbon coated. The grids of sections were 
viewed using a Jeol JEM-1200 EX electron microscope. At least 100 cells 
were counted per sample, cells were identified, and morphological dif-
ferences were recorded. Cells were scored for the presence of dilated ER 
(indicative of ER stress), as follows: 1, cells containing dilated ER segments 
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